Participants sought: Adjunctive Hormone treatment for people with schizophrenia

Men and women who are 18+, with schizophrenia or schizoaffective disorder, are invited to be involved in an adjunctive treatment study that is underway in Melbourne. Hormones are known to play a role in the expression of schizophrenia and related disorders. The Monash Alfred Psychiatry research centre is investigating whether a treatment that targets hormones, when taken in combination with regular antipsychotic medication, can better improve psychotic symptoms, mood and cognitive functioning. Participants will be reimbursed for their time and travel can be negotiated.  See more: Link

Participants sought: Medication in smoking cessation

This MAPrc study will examine important safety aspects (such as agitation, aggression and depression) of the drugs varenicline and bupropion compared to placebo (“dummy pills” that do not contain any medicine) and nicotine-replacement therapy (NRT or “the patch”) in smokers with or without a history of being diagnosed with a psychiatric disorder. See more: Link

Participants sought: Predicting optimized treatment in depression

MAPrc is investigating patient response versus non patient response (i.e “controls” – defined as participants who do not suffer from depression and are not on medication) to antidepressant medications. A combination of brain measures (physical and mental) and body functions will be analysed to determine patient response to antidepressant medications using genetic, psychological and physiological measures. Currently, there are no accurate predictors of how patients will respond to antidepressant treatment. We would love to hear from you: Link